Menu
Menu
Menu
Telum Therapeutics Development Pipeline
Within our pipeline we have specific programs to treat serious multidrug-resistant
Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa
Program / Product
Pathogen
Discovery
Preclinical
Patent
Ongoing
Future
P001/TT206 (GN EPLE)
Enterobacteriaceae, Pseudomonas aeruginosa Acinetobacter baumannii, including cabapenem resistant strains.
Life-threatening bacteremia
PCT/EP2021/056264
PO02/TT052 (GN EPLE)
Acinetobacter baumannii CRA
Serious infections
Patent application underwriting
PO03 (GN&GP EPLE)
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Cystic Fibrosis
PO04 (GN EPLE)
Enterococcus faecium VRE
Nosocomial infections
PO05 (GN EPLE)
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
Serious infections and Skin infections
Program
P001/TT206 (GN EPLE)
Pathogen
Enterobacteriaceae, Pseudomonas aeruginosa Acinetobacter baumannii, including cabapenem resistant strains.
Discovery & Preclinical
Life-threatening bacteremia
Patent
PCT/EP2021/056264
Program
PO02/TT052 (GN EPLE)
Pathogen
Acinetobacter baumannii CRA
Discovery & Preclinical
Serious infections
Patent
Patent application underwriting
Program
PO03 (GN&GP EPLE)
Pathogen
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Discovery
Cystic Fibrosis
Patent
Program
PO04 (GN EPLE)
Pathogen
Enterococcus faecium VRE
Discovery
Nosocomial infections
Patent
PCT/EP2021/056564
Program
PO05 (GN EPLE)
Pathogen
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
Discovery
Preclinical
Serious infections and Skin infections
Patent
Abbreviations: EPLE: Engineered Phage Lytic Enzyme; GN, Gram negative bacteria; GP, Gram positive bacteria; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp
